Biotech and Pharmaceuticals Life Sciences

More

  • Dec 16- Array BioPharma Inc said its experimental drug helped patients with a form of melanoma live longer without their cancer progressing, in an ongoing late-stage study. The company's stock jumped about 24 percent before the opening bell on Wednesday. The stock closed at $3.83 on the Nasdaq on Tuesday.

  • Dec 16- Drug developer Array BioPharma Inc said its experimental drug helped patients with a form of melanoma live longer without their cancer progressing, in a late-stage study.

  • Attention China: You can buy cans of clean Canadian air

    Harrison Wang, China spokesperson of Vitality Air, explains the concept behind the Canada-based company which sells cans of clean air.

  • PARIS, Dec 9- Sanofi's dengue vaccine is to make its market debut in Mexico, the French drugmaker said on Wednesday, adding that it expects to have filed for market approval in some 20 countries by year-end. Sanofi Pasteur, the group's vaccines division, said Mexico had approved the preventive treatment, called Dengvaxia, for all four dengue virus serotypes, but...

  • Dec 8- The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc's treatment for an ultra-rare and potentially fatal genetic disorder. Alexion shares were up $8.07, or 4.5 percent, at $187.22. There are only a few thousand patients with LAL-D in the United States, Alexion said.

  • Dec 8- The U.S. Food and Drug Administration approved Alexion Pharmaceutical Inc's treatment for a rare genetic disorder that could lead to multi-organ damage and death. Kanuma, which was added to the drugmaker's pipeline in June through its acquisition of Synageva BioPharma Corp, could be priced $300,000 to $400,000 annually, MorningStar Inc analyst Stefan...

  • Dec 8- The U.S. Food and Drug Administration on Tuesday approved Alexion Pharmaceutical Inc's treatment for a rare and potentially fatal genetic disorder. Alexion's enzyme-replacement therapy, Kanuma, aims to treat patients with lysosomal acid lipase deficiency, a type of genetic disorder that often leads to multi-organ damage and premature death.

  • The FDA approved the vaccine, BioThrax, for use in patients who are between 18-65 years of age in conjunction with antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure. It is the only FDA- licensed vaccine for the disease.

  • FDA approves Emergent Biosolution's anthrax vaccine Monday, 23 Nov 2015 | 5:51 PM ET

    Nov 23- The U.S. Food and Drug Administration approved Emergent BioSolutions Inc's anthrax vaccine to prevent suspected or confirmed exposure to the bacterium that causes the disease. The FDA approved the drug, BioThrax, for use in patients who are between 18-65 years of age, in conjunction with recommended antibiotic treatment. BioThrax was first approved by...

  • *Pfizer, Allergan drop after biggest-ever healthcare deal. Pfizer's shares were down 2.1 percent at $31.51, after the company said it would buy fellow drugmaker Allergan in a deal valued at about $160 billion, the biggest ever in the healthcare sector. Allergan fell 2.4 percent to $305.11.

  • *Allergan, Pfizer drop after biggest-ever healthcare deal. Pfizer's shares fell 3 percent to $31.20, after the company said it would buy Allergan in a deal valued at about $160 billion, the biggest ever in the healthcare sector. The two stocks were the biggest drags on the S&P 500, while Pfizer was the biggest drag on the Dow.

  • *Allergan, Pfizer drop after biggest-ever healthcare deal. *Alcoa up on report of Elliott stake, boosts materials. Pfizer's shares fell 2 percent to $31.54, after the company said it would buy Allergan in a deal valued at about $160 billion, the biggest ever in the healthcare sector.

  • *Allergan, Pfizer drop after biggest ever healthcare deal. *Mallinckrodt up after posting higher sales. Nov 23- U.S. stock indexes were set to open little changed on Monday, coming off last week's strong gains, as investors head into Thanksgiving week.

  • *Biogen to market biosimilar etanercept in Europe. LONDON, Nov 20- A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators. Worldwide sales of Amgen's Enbrel, which is marketed outside North America by...

  • Nov 19- U.S. drugmaker Pfizer and France's Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers. Cellectis said on Thursday that Servier had exercised an option to acquire the exclusive worldwide rights to UCART19, which is about to enter initial Phase I clinical tests, and Pfizer would...

  • LONDON, Nov 18- Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their...

  • SAN FRANCISCO, Nov 17- Gender diversity in the San Francisco Bay Area technology sector has improved over the last five years, but the region's most gender-diverse businesses are in the retail, biopharmaceuticals and financial services sector, a new study from the University of California, Davis, found. Out of the 223 largest publicly traded companies...

  • Nov 17- Shares in Genmab jumped 11 percent on Tuesday after U.S. regulators approved an experimental blood cancer drug that the Danish biotech company licensed in 2012 to Johnson& Johnson. The U.S. Food and Drug Administration said late on Monday it had approved Darzalex for patients who had already undergone at least three prior standard treatments for...

  • SAN FRANCISCO, Nov 17- Gender diversity in the San Francisco Bay Area technology sector has improved over the last five years, but the region's most gender-diverse businesses are in the retail, biopharmaceuticals and financial services sector, a new study from the University of California, Davis, found. Out of the 223 largest publicly traded companies...

  • Nov 16- Shares of Nexvet Biopharma Plc rose as much as 33 percent after the animal-health company's drug for canine osteoarthritis showed promise in a study. Dogs enrolled in the study experienced relief from pain at four weeks when compared with placebo, the company said, adding that the results would form the basis for a regulatory application with the U.S....